SHARE:   Share to Facebook Share to Twitter Share to Linked In Share via Email  

Back To Search Results

C153 - Alzheimer's Dementia: Diagnosis and Treatment

Event Time: Wednesday April 26, 2017 7:00 am to 9:00 am
Topic(s): Aging, Dementia, Cognitive, and Behavioral Neurology
Director(s): David Knopman MD, FAAN
Description: This program will focus on important issues in the diagnosis of cognitive impairment due to Alzheimer's disease. We will discuss advanced topics in clinical diagnosis, the role of genetics in diagnosis and information for patients and families, the role of clinical and experimental imaging in the diagnosis of AD, and where we stand with treatment for AD.
Completion Message: Participants should be able to describe the continuum of cognitive function in the Alzheimer spectrum; understand the major and minor genetic influences on AD, describe the evolving biomarker diagnostic process for defining AD as a pathophysiology, and describe the appropriate indications for cholinesterase inhibitors and memantine.
CME Credits: 2
Core Competencies: Patient Care, Medical Knowledge

Program Speakers - Tentative

Start/End Time Title Faculty
7:00 AM - 7:30 AM The Clinical Diagnosis of MCI and Dementia Due to AD Richard J. Caselli MD, FAAN 
7:30 AM - 7:40 AM Controversies in Nosology of MCI and Dementia: What’s New? David S. Knopman MD, FAAN 
7:40 AM - 8:05 AM Biomarkers for the Diagnosis of AD David S. Knopman MD, FAAN 
8:05 AM - 8:30 AM The Role for Genetics in AD Diagnosis and Management Richard J. Caselli MD, FAAN 
8:30 AM - 8:50 AM Therapeutics in AD for 2017 and the Near Term David S. Knopman MD, FAAN 
8:50 AM - 9:00 AM Questions and Answers Faculty 

Disclosures

Speaker Disclosure
Richard J. Caselli, MD, FAAN Dr. Caselli has nothing to disclose.

David S. Knopman, MD, FAAN Dr. Knopman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Lundbeck Pharmaceuticals and the DIAN study. Dr. Knopman has received research support from Biogen Pharmaceuticals and Lilly Pharmaceuticals.

Register Now

Related Courses

Saturday April 21, 2018

7:00 AM-9:00 AM
C1 Mild Cognitive Impairment: Implications for Clinicians Ronald Petersen PhD, MD, FAAN
9:30 AM-11:30 AM
C13 Neuroimaging Biomarkers Across the Dementia Spectrum Liana Apostolova MD, FAAN
C10 More than Medicine: How to Access Home Care, Support Caregivers, and Discuss Complex Situations in Advanced Neurologic Disease Farrah Daly MD, MBA
1:30 PM-3:30 PM
C20 The Neurology of Social Behavior Bradford Dickerson MD

Sunday April 22, 2018

7:00 AM-9:00 AM
C33 Clinicopathological Correlation Session in Dementia David Irwin MD
1:00 PM-3:00 PM
S2 Aging and Dementia Platform Session

Friday April 27, 2018

7:00 AM-9:00 AM
C219 The Early-Onset Dementias Mario Mendez MD, PhD, FAAN
12:00 PM-12:45 PM
Outsmart Stress Marie Pasinski MD
1:00 PM-3:00 PM
C227 Behavioral Neurology: A Case-based Approach A. Barrett MD, FAAN
S48 Aging and Dementia Platform Session
3:30 PM-5:30 PM
C238 Memory Disorders: A Case-based Approach David Wolk MD

MEMBER LOG IN

Forgot Password?